Cargando…

Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis

BACKGROUND: Natural allergen sources can supply large quantities of authentic allergen mixtures for use as immunotherapeutics. However, such extracts are complex, difficult to define, vary from batch to batch, which may lead to unpredictable efficacy and/or unacceptable levels of side effects. The u...

Descripción completa

Detalles Bibliográficos
Autores principales: Glenting, Jacob, Poulsen, Lars K, Kato, Kentaro, Madsen, Søren M, Frøkiær, Hanne, Wendt, Camilla, Sørensen, Helle W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000909/
https://www.ncbi.nlm.nih.gov/pubmed/17711578
http://dx.doi.org/10.1186/1475-2859-6-28
_version_ 1782135559612792832
author Glenting, Jacob
Poulsen, Lars K
Kato, Kentaro
Madsen, Søren M
Frøkiær, Hanne
Wendt, Camilla
Sørensen, Helle W
author_facet Glenting, Jacob
Poulsen, Lars K
Kato, Kentaro
Madsen, Søren M
Frøkiær, Hanne
Wendt, Camilla
Sørensen, Helle W
author_sort Glenting, Jacob
collection PubMed
description BACKGROUND: Natural allergen sources can supply large quantities of authentic allergen mixtures for use as immunotherapeutics. However, such extracts are complex, difficult to define, vary from batch to batch, which may lead to unpredictable efficacy and/or unacceptable levels of side effects. The use of recombinant expression systems for allergen production can alleviate some of these issues. Several allergens have been tested in high-level expression systems and in most cases show immunereactivity comparable to their natural counterparts. The gram positive lactic acid bacterium Lactococcus lactis is an attractive microorganism for use in the production of protein therapeutics. L. lactis is considered food grade, free of endotoxins, and is able to secrete the heterologous product together with few other native proteins. Hypersensitivity to peanut represents a serious allergic problem. Some of the major allergens in peanut have been described. However, for therapeutic usage more information about the individual allergenic components is needed. In this paper we report recombinant production of the Ara h 2 peanut allergen using L. lactis. RESULTS: A synthetic ara h 2 gene was cloned into an L. lactis expression plasmid containing the P170 promoter and the SP310mut2 signal sequence. Flask cultures grown overnight showed secretion of the 17 kDa Ara h 2 protein. A batch fermentation resulted in 40 mg/L recombinant Ara h 2. Purification of Ara h 2 from the culture supernatant was done by hydrophobic exclusion and size separation. Mass spectrometry and N-terminal analysis showed a recombinant Ara h 2 of full length and correctly processed by the signal peptidase. The immunological activity of recombinant Ara h 2 was analysed by ELISA using antibodies specific for native Ara h 2. The recombinant Ara h 2 showed comparable immunereactivity to that of native Ara h 2. CONCLUSION: Recombinant production of Ara h 2 using L. lactis can offer high yields of secreted, full length and immunologically active allergen. The L. lactis expression system can support recombinant allergen material for immunotherapy and component resolved allergen diagnostics.
format Text
id pubmed-2000909
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-20009092007-10-05 Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis Glenting, Jacob Poulsen, Lars K Kato, Kentaro Madsen, Søren M Frøkiær, Hanne Wendt, Camilla Sørensen, Helle W Microb Cell Fact Research BACKGROUND: Natural allergen sources can supply large quantities of authentic allergen mixtures for use as immunotherapeutics. However, such extracts are complex, difficult to define, vary from batch to batch, which may lead to unpredictable efficacy and/or unacceptable levels of side effects. The use of recombinant expression systems for allergen production can alleviate some of these issues. Several allergens have been tested in high-level expression systems and in most cases show immunereactivity comparable to their natural counterparts. The gram positive lactic acid bacterium Lactococcus lactis is an attractive microorganism for use in the production of protein therapeutics. L. lactis is considered food grade, free of endotoxins, and is able to secrete the heterologous product together with few other native proteins. Hypersensitivity to peanut represents a serious allergic problem. Some of the major allergens in peanut have been described. However, for therapeutic usage more information about the individual allergenic components is needed. In this paper we report recombinant production of the Ara h 2 peanut allergen using L. lactis. RESULTS: A synthetic ara h 2 gene was cloned into an L. lactis expression plasmid containing the P170 promoter and the SP310mut2 signal sequence. Flask cultures grown overnight showed secretion of the 17 kDa Ara h 2 protein. A batch fermentation resulted in 40 mg/L recombinant Ara h 2. Purification of Ara h 2 from the culture supernatant was done by hydrophobic exclusion and size separation. Mass spectrometry and N-terminal analysis showed a recombinant Ara h 2 of full length and correctly processed by the signal peptidase. The immunological activity of recombinant Ara h 2 was analysed by ELISA using antibodies specific for native Ara h 2. The recombinant Ara h 2 showed comparable immunereactivity to that of native Ara h 2. CONCLUSION: Recombinant production of Ara h 2 using L. lactis can offer high yields of secreted, full length and immunologically active allergen. The L. lactis expression system can support recombinant allergen material for immunotherapy and component resolved allergen diagnostics. BioMed Central 2007-08-21 /pmc/articles/PMC2000909/ /pubmed/17711578 http://dx.doi.org/10.1186/1475-2859-6-28 Text en Copyright © 2007 Glenting et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Glenting, Jacob
Poulsen, Lars K
Kato, Kentaro
Madsen, Søren M
Frøkiær, Hanne
Wendt, Camilla
Sørensen, Helle W
Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis
title Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis
title_full Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis
title_fullStr Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis
title_full_unstemmed Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis
title_short Production of Recombinant Peanut Allergen Ara h 2 using Lactococcus lactis
title_sort production of recombinant peanut allergen ara h 2 using lactococcus lactis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000909/
https://www.ncbi.nlm.nih.gov/pubmed/17711578
http://dx.doi.org/10.1186/1475-2859-6-28
work_keys_str_mv AT glentingjacob productionofrecombinantpeanutallergenarah2usinglactococcuslactis
AT poulsenlarsk productionofrecombinantpeanutallergenarah2usinglactococcuslactis
AT katokentaro productionofrecombinantpeanutallergenarah2usinglactococcuslactis
AT madsensørenm productionofrecombinantpeanutallergenarah2usinglactococcuslactis
AT frøkiærhanne productionofrecombinantpeanutallergenarah2usinglactococcuslactis
AT wendtcamilla productionofrecombinantpeanutallergenarah2usinglactococcuslactis
AT sørensenhellew productionofrecombinantpeanutallergenarah2usinglactococcuslactis